Method for rehabilitation treatment of oncogynaecologic patients of reproductive age suffering uterine corpus and cervical cancer and received anticancer therapy

FIELD: medicine.

SUBSTANCE: method involves successive normobaric hypoxytherapy and EHF therapy. The normobaric hypoxytherapy is conducted with using the amount of oxygen in gas mixture from 18% to 10%. The exposure is cyclic-phase. A mixture respiration cycle makes 5 minutes and follows atmospheric air respiration for 5 minutes. One respiration session involves 5-7 these cycles. That is followed by EHF therapy at wave length 7.1 mm, power 10 mWt/cm2. The exposure covers 2-6 biologically active points found in reflexogenic zones.

EFFECT: improving cell respiration and tissue trophism, increasing total resistance and body adaptability, enhancing detoxification processes, eliminating post-radiation impaired haemopoiesis, reducing immunodepression processes, and improving the patient's quality of life.

1 ex, 1 tbl

 

The invention relates to medicine and can be used in Oncology and regenerative medicine.

Various methods of rehabilitation treatment in malignant tumors after a standard course of antineoplastic treatment(1, 2, 3, 4). Cancer patients after specific antitumor treatment need in the treatment of complications associated with the disease itself and treatment given (surgery, radiology, chemotherapy), and the correction of comorbidities. Cancer and subsequent surgery is the cause of pre - and postoperative stress, leading to mental and physical fatigue, great stress on the body's defenses, decrease its adaptive possibilities. Chemotherapy is accompanied by a massive collapse of the tumor cells, endogenous intoxication, which can manifest changes of the blood and internal organs (heart, liver, and peripheral nerves. Radiological treatment may contribute to immunosuppression, the development of asthenovegetative syndrome, adversely affect the composition of the blood, cause pain in the limbs.

Of particular concern is the effects that are observed in the localization of the cancer process in hormone-dependent and hormone�producing organs, especially in cancer of the cervix and uterus in patients of reproductive age. After radical treatment, leading to the shutdown of ovarian function and hormone deficiency, are developing a complex reaction of the neuroendocrine system, which is connected with the processes of adaptation of the female organism to new conditions. Quick shutdown of ovarian function, deficiency of hormones on the background of stress, endogenous intoxication, changes in immune reactivity lead to the development of an artificial menopause with complex emotional symptom.

Various methods of rehabilitation treatment of cancer patients after specific treatment using both drugs (natural and synthetic immunomodulators, adaptogens, cytokines, vitamin therapy) and physical factors (magnetotherapy, indifferently isothermal bathing and drinking the mineral waters, therapeutic exercises) (5, 6, 7, 8, 9, 10, 11). The inclusion of physical methods in the treatment can reduce the degree of intoxication, modulate immunological reactivity of the organism. The advantage of the use of physical factors is the possibility of their influence on the main pathogenetic mechanisms of development of desadaptado, the activation of stress-limiting systems whose functioning is not enough PR� long flowing chronic pathological processes.

However, insufficient in some cases the effectiveness of treatment, additional drug load on the background of existing endogenous intoxication, restriction of the use of a number of factors, the short term remission, the tendency to recurrence of the disease require changing tactics, finding new and further development of proven tools and techniques to enhance the physiological reserves of the body, correction of psychological and somatogenic disorders, preservation of health.

The closest in technical essence (the prototype) to the claimed method is a method of reducing the side effects of ionizing radiation on the organism of the patient before and during the sessions with external beam radiotherapy (12).

The disadvantages of this method include the complexity of procedure combined remote gamma-therapy, increasing its duration, and the use of hypoxic during the course of radiation therapy, while the symptoms of endogenous intoxication, fatigue, psycho-emotional disorders persist in the future for a long period of time to a considerable extent.

The object of the invention is the creation of a highly effective method of rehabilitation treatment of cancer patients of reproductive age, improving their quality of life.

Put for�Acha solved by more consistent application after normobaric hypoxic treatments of electromagnetic radiation grinevesky frequency (EHF EMR) with a wavelength of 7.1 mm, 10 mW/cm22-6 biologically active points located in reflexogenic zones. Patients of reproductive age with cancer of the body and cervix IB-IIB stage in the absence of metastasis and recurrence in a period of 3 to 6 months after completion of anticancer treatment procedure normobaric hypoxic hypoxic gas mixture with an oxygen content of 18% to 10% cyclic-phase mode: breathing mixture from 2 to 5 minutes, then breathing atmospheric air - 5 min (one cycle). The number of cycles in one session 5-7, the total time 30-50 min After the session of Belarus carried out the influence of EHF EMR waves (wavelength of 7.1, 10 mW/cm2) on biologically active points RP6 and VC17 consistently. In the presence of concomitant respiratory diseases in the recipe include points P5, R3, V43, diseases of the gastrointestinal tract - point GL10, RP4, V43, R7, VB34, for kidney disease - RP4, R3, R7. The exhibition is 5 minutes per point, used for a session of 2 to 6 points. Procedures carried out daily, for a course of 10-12 sessions.

New in the claimed method is the additional application of successive treatments of EHF EMR therapy with a wavelength of 7.1 mm, 10 mW/cm2on RP6 and VC17 biologically active points located in the reflex areas and 5 minutes for each point, a daily buffet Breakfast are provided�about, the course is 10-12 procedures.

The choice of physical factors due to their mechanism of action and results of clinical trials. Normobaric hypoxic therapy is a physical factor in the multifaceted actions: improves oxygen transport, cellular respiration and trophic tissues; increases the overall resistance and adaptive forces of the body; enhances the detoxification processes; promotes elimination of radiation-human blood; reduces symptoms of immunosuppression, and improves the course of concomitant somatic diseases.

To enhance protivocesterngo operation, reduce symptoms neurovegetative and psycho-emotional symptoms in the medical complex was put EHF EMR exposure. EHF EMR potentiates anti-stress effect, normalizes reactivity of sympathoadrenal link of the vegetative nervous system which helps to eliminate such manifestations of climacteric syndrome as a frequent hot flushes, irritability, tension, restlessness, tearfulness, poor sleep, depression.

The combined effects of normobaric hypoxic therapy and EHF EMR is well tolerated and does not cause tumor growth.

Distinctive features showed in the inventive combination of new properties that are not explicitly derived from the prior art in this region�STI, and not obvious for the expert.

Identical set of features not found in the patent and scientific and medical literature.

Proposed as a method of the invention can be used in practical health care to improve the treatment of cancer patients and improve their quality of life.

Based on the foregoing should be considered the present invention with the relevant conditions of patentability of "Novelty", "Inventive step" and "Industrial applicability".

The method is as follows:

Daily, in the morning spend the session normobaric hypoxic. Before screenings measure blood pressure, count the pulse rate, examine a sample of the Bar - the breath on the inhale with a fixed duration. When the value of the breath to 10 with a single hypoxic cycle - 2 min, from 10 to 20 s - 3 min, from 20 to 30 s to 4 min, 30 s - 5 min. Per session spend 5-7 cycles. Then sequentially exposed to EHF EMR with a wavelength of 7.1 mm, 10 mW/cm2on biologically active points RP6 and VC17, located in reflexogenic zones by 5 minutes for each point, every day, at the rate of 10-12 procedures.

Description clinical research.

Under supervision there were 63 patients with gynecological cancer Zab�levaniali (cervical cancer IB and IIB and stage cancer of the uterine body IB and IIB stage), aged 26 to 46 years, which resulted in combined anticancer treatment in accordance with the localization, stage of the process, histological type of tumor. Thirty-three patients in the period from 3 to 6 months after completion of anticancer therapy were treated according to the claimed process (major group 1). Control (2) group consisted of 30 patients who after the completion of the combined anticancer treatment were treated by the inventive method. The composition of the group of patients, clinical signs were comparable.

Patients of both groups were surveyed: before treatment underwent standard clinical examination, including bimanual examination, smear test, smear on the vaginal microflora, clinical and biochemical blood tests (KLA, OAM, blood chemistry, lipid profile, coagulation, determination of cortisol, ACTH, insulin in the serum), the hormonal profile: estradiol, FSH, LH, testosterone, immune status. Also all performed consultation, ECG, ultrasound of pelvis, liver, kidney, radiography of the chest, mammography. In addition, it was performed the determination of the level of anxiety and depression using HADS; level neurovegetative disorders scales with the menopausal castroist� Cooperman modifications in E. V. Uvarov, count kerdo index. Quality of life was assessed on a scale of EORTC QLQ 30 with a special module for cancer patients EORTC 28 GLG.

Dynamic monitoring was performed prior to treatment of the claimed method, after treatment, and at 3, 6, 12 months.

Mathematical analysis of the data was performed using the software package Statictica of 6.0. Applied nonparametric statistical tests Mann-Whitney, Fisher criteria. Differences were considered significant at p<0,05.

The impact of the proposed medical complex on neurovegetative manifestations of climacteric syndrome and quality of life indicators presented in table 1.

Table 1
The impact of rehabilitation complex on neurovegetative manifestations of climacteric syndrome and quality of life in women undergoing anticancer treatment
The studied parameterThe group of patientsBefore the treatmentAfter the treatmentAfter 3 monthsAfter 6 months12 months
Index Ku�permana-Uvarova (points) 124,1±5,112,4±0,4*15,1±5,415,1±6,818,2±6,2
223,1±3,126,4±2,123,1±5,119,8±4,223,1±3,9
The kerdo index (%)
eutonia16,06±0,127,3±0,2*21,2±0,518,8±0,618,2±1,4
26,6±0,26,6±0,29,2±1,29,9±1,06,6±0,2
The predominance of the sympathetic system160,6±2,242,4±3,1*39,4±3,639,4±4,048,4±5,2
256,1±3,1of 55.4±2,752,8±4,149,5±3,1 56,4±4,1
The predominance of the influence of the parasympathetic system133,4±2,630,3±2,739,4±2,844,8±3,433,4±2,5
237,3±1,938,0±4,034,0±4,040,6±3,737,0±3,1
Scale HADS (score)

7,1±0,3 56,7±2,2*
Alert level19,1±0,136,1±0,12*7,0±0,37,1±2,18,03±0,18
29,5±0,39,4±0,3at 9.38±0,39,37±0,39,8±0,39
The level of depression17,5±0,26,2±0,3*6,2±0,46,8±0,17,0±0,1
27,06±0,58at 6.92±0,287,02±0,327,1±0,2
Scale of quality of life EORTC QLQ 30 with the module EORTC QLQ 28 (points)
Overall health160,4±4,0-68,3±5,167,6±9,462,1±6,7
262,0±7,062,9±4,662,2±5,8the 61.8±6,1
Physical functioning171,1±2,6-79,4±3,477,0±2,174,3±3,8
270,6±5,0-70,8±4,771,4±6,070,1±5,2
Emotional functioning146,3±4,0-58,2±3,1*54,0±3,2
247,0±3,7-48,2±0,947,2±4,447,8±6,1
Social functional155,9±3,2-67,6±3,9*65,0±2,1*62,3±5,1
256,3±4,1-58,6±5,057,1±4,657,7±4,1
Note: * - reliability of p<0,05

As can be seen from table 1, the study group before treatment had no significant differences in the studied parameters.

The overwhelming number of patients to rehabilitation treatment was observed autonomic disorders of moderate severity, fatigue, decreased quality of life.

Under the influence of a rehabilitation complex in patients with decreased number of tides (94%), decreased sweating (94%), improved sleep (91%), decreased irritability (87,9%), tearfulness (94%), asthenia (69,7%), headaches disappeared (72,7%).

As can be seen from table 1, the index of Supermaneuverable after treatment decreased significantly (p< 0,05), continued to be lower and to the end of the year did not return to the initial parameters. In the control group no significant changes were made, vegetative indices were changed to a lesser extent.

Counting kerdo index showed a decrease of the influence of the sympathetic division of the autonomic nervous system in the main group after a course of rehabilitation (p<0.05) and the increase in patients with autonomic balance (eutonia) (p<0,05). In the control group no significant changes were not revealed.

Analysis of the indicators of the emotional state of patients found that the level of anxiety and level of depression decreased in patients of the first group (p<0.05) and remained lower during the first 6 months, then growing to the end of the year. The indicators of control of the group during the year remained almost unchanged.

Assessment of quality of life indicators on a scale of EORTC QLQ 30 module

EORTC QLQ 28 has established a positive trend in the Foundation of the group in terms up to 6 months after completion of treatment. This was expressed in a statistically significant increase in the levels of emotional and social functioning, as well as in a trend of increase in the General level of health and physical functioning.

Improvement was also confirmed by the increase in the content of hemoglobin (122,9±0,82; HR 132.5±0,63, p<0.05) and erythrocyte (4,0±0,02; 4,3±0,3, p<0,05) after rehabilitation treatment in patients of the main group. In the control group these figures were not changed significantly.

Negative dynamics and signs of recurrence of the disease in the observed patients over the subsequent 5 years of follow-up has not been established. Survival rates in the main group of 93.5% in the control group, 92%.

Example:

Patient B-ova, 49 years old, an engineer, was on rehabilitation in CR "Keys" in February 2010 on the occasion of climacteric syndrome of moderate severity, degenerative disc disease of the lumbar-sacral spine in remission. In 2009 underwent a combined treatment for cancer of the uterine body article IIB surgery - extended hysterectomy with appendages, a course of DHT to the settings pane in ODS 49 Gr. Of no relapse.

When you receive a complaint of depressed mood, anxiety, hot flushes up to 5-6 times a day, irritability, poor sleep, sweating.

Survey data at admission:

KLA - hemoglobin 129, erythrocytes 4,73, leukocytes 5,9, platelets 258, ESR 13 mm/h.

OAM - C/W, transparent, protein OTP, SP. weight. 1020, pH 6.0, leukocytes 2-4 in p/Zr, single flat epithelium in the field of view.

Biochemical analysis of blood - glucose of 5.6, protein 71, urea 5,2, bilirubin is a 10.1-0-10,1, AST 24, ALT 19.

Coagulation - PTV - 14, APTT - 29, total fibrinogen ,5, TV 14, rfmk 3, TH test neg MHO 1,0

Radiography WGC in her lungs for no apparent focal and infiltrative changes.

Mammography - nodule no.

ECG - sinus rhythm, heart rate of 74 UDM. EOS is not rejected.

Abdominal ultrasound signs of chronic cholecystitis.

Pelvic ultrasound - status post hysterectomy.

Therapist consultation - chronic cholecystitis article remission

Consult a gynecological oncologist - Cr corpus uteri gradus sec. The condition after the combined treatment in 2009 of no Relapse.

Cytology No. 8736 - cells stratified squamous epithelium.

Smear on flora - the leukocyte count to 10 in p/Zr, an epithelium flat, in a single field of view.

During treatment with CR "Keys" took 10 sessions of normobaric hypoxic therapy in combination with EHF EMR (wavelength of 7.1 mm, power 10 mW/cm2) at the point RP6 and VC17 5 minutes for each point.

The procedure was well tolerated clinically severe balneologie was not.

By the end of treatment decreased irritability, tearfulness, significantly improved mood, better sleep, number of flushes decreased to 1-2 per day.

The KLA after treatment - hemoglobin 136, erythrocytes 4,96, leukocytes 5,9, 268 platelet, ESR 15 mm/h.

OAM - C/W, transparent, protein OTP, SP. weight.1022, pH 6.0, leukocytes 1-2 in field of view, flat cell epithelium isolated.

As a result Leche�Oia noted positive dynamics of the level of neurovegetative manifestations.

Index Cooperman-Uvarova (points) - before the treatment of 24.6±3,1, after treatment of 12.6±2 (p<0,05).

Anxiety level on a scale HADS - before the treatment of 9.4±0,11, after treatment of 5.9±0,11 (p<0,05).

The level of depression scale HADS - before treatment 7,8±0,1 after treatment 6,0±0,2 (p<0,05).

The patient was observed after 3, 6, 12 months and annually thereafter until 2014. Signs of recurrence of the disease is not, work at your previous job.

Dynamics of quality of life on a scale of EORTC QLQ 30 with the module EORTC QLQ 28 (points).

Overall healthBefore the treatmentAfter 3 monthsAfter 6 months12 monthsAfter 3 years
60,6±2,069,4±4,268,6±9,264,3±5,263,2±3,1
Physical functioning70,1±1,880,4±2,378,0±1,174,2±4,173,2±1,2
Emotional funk�working 44,2±4,059,2±3,1*56,6±2,1*55,6±2,054,0±2,1
Social functioning55,7±4,269,1±3,9*67,2±3,1*64,3±2,962,1±3,1
Note:*- reliability of differences p<0,05

As follows from the data as a result of treatment, the patient declined the index Cooperman-Uvarova, decreased the influence of the sympathetic division of the autonomic nervous system, decreased levels of anxiety and depression, improved quality of life.

Any negative dynamics and signs of recurrence of the disease from 2009 to 2014, the patient was not identified.

Thus, the inventive method of rehabilitation treatment of gynecological cancer patients of reproductive age after antitumoral treatment showed good efficiency in respect of neurovegetative menopausal syndrome, the ability to improve the quality of life of these patients in the absence of signs of recurrence SDA�olevaga disease.

The list of references

1. Grushina T. I. recommendations for the direction of the cancer patients to sanatorium-resort treatment (T. I. Grushin) // Physiotherapy, balneology and rehabilitation - 2003 - No. 3 - pp. 49-51.

2. Grushina T. I. Rehabilitation in Oncology: physical Therapy / T. I. Grushin. - M.: GEOTAR-Media, 2006. - p. 5-26.

3. Grushina T. I. Physical factors in rehabilitation of patients with oral cancer undergoing laryngectomy. Physiotherapy, balneotherapy and rehabilitation. 2004, 4, pp. 9-14.

4. Kunduhova E. M., Vegova L. I., Proteins A. S. Medical rehabilitation of patients with cervical cancer. - In kN.: Contemporary issues in the treatment and rehabilitation of cancer patients: Tutorial. Tr. - M., 1984. Pp. 166-169.

5. Mokeev M. V., Radionov, V. A., A. V. Yashkov, Molkov V. K. Influence of sanatorium-resort treatment with mineral water on the dynamics of immune parameters of patients operated on for cancer of the thyroid gland. / Modern tendencies and prospects of development of resort business in the Russian Federation. Materials: Intern. Congress health Resort" - 2009, p. 150.

6. Olejnik N. N. Principles of medical rehabilitation of patients, radical surgery for cervical cancer. - In kN.: Rehabilitation of patients with malignant neoplasms: Rep. scientific. Conf. - Vinnitsa, 1982. Pp. 166-168.

7. Afonichev O. G., Kuznetsova O. V. Lymphatic drainage. Novokuznetsk. 2000, pp. 3-36.

8. Shabashova N. I., Nurmukhamedov A. I., Mirotvorcev K. S., Uzunova, V. G., Shashkov, N. G. Trends in rehabilitation treatment of patients with endometrial cancer. - In kN.: Early diagnostics and treatment of precancerous and cancer of the cervix and clinical examination of the female population.: The Union reports. Symp. - L., 1985. - Page 179-182.

9. Hernandez Munoz G. Cimicifuga racemosa for the treatment of hot Hashes in women surviving breast cancer / G. Hernandez Munoz, S. Pluchino // Maturitas. - 2003. - Vol.44. - Supl.1. - P. 59-65

10. Mueck A. O. Hormone therapy after endometrial cancer / A. O. Mueck, N. Seeger // Endocrine-related cancer. - 2004. - Vol.11. - P. 305-314.

11. Warburton D. E. R. Health benefits of physical activity / D. E. R. Warburton, C. W. Nicol, and S. S. Bredin // The Canadian Medical Association Journal. - 2006. - Vol.174. - P. 801-809.

12. Strelkov R. B., Chizhov A. J. "Ways to reduce the side effects of ionizing radiation on the organism of the patient during external beam radiotherapy". M., Ministry of health of the USSR, 1975, pp. 1-6

13. Tsyb A. F., Yarmolenko, S. P., Strelkov R. B., Y. S. Mardin, Chizhov A. J., Golubenko G. V. "Hypoxidaceae patients with malignant tumors. - Moscow-Obninsk, USSR Ministry of health, 1985.

14. Strelkov R. B., Marzynski Y. S., Firsov p. P., Chizhov A. J. "a Method for reducing the side effects of ionizing radiation on the patient's body remote therapy for breast cancer". - Obninsk, USSR Ministry of health, 1984. pp. 1-6.

Method of rehabilitation treatment of gynecological cancer patients of reproductive age with cancer of the body and cervix IB and IIB Stepa�and no signs of metastasis in 3-6 months after antitumoral treatment, includes the procedure of normobaric hypoxic therapy with the amount of oxygen in hypoxic gas mixture from 18% to 10% cyclic-phase mode: one cycle of breathing a mixture of 2-5 min, then 5 min atmospheric air, 5-7 cycles per session, characterized in that it further sequentially perform the procedure the impact of EHF waves with a wavelength of 7.1 mm 10 mW/cm2on biologically active points RP6 and VC 17 to 5 minutes for each point daily in the course of 10-12 procedures.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel hetericyclic compounds of general formula or to its tautometric form, or to its pharmaceutically acceptable salt, where 1-2 of X1, X2, X3, X4, X5, X6 is selected from N, and the remaining ones represent C, X7 is selected from N or CH; each of X8, X9, X10 and X11 is independently selected from N or CH on condition that fragment can simultaneously contain one or two nitrogen atoms; R1, R2, R3 and R4 are selected from H, 6-memberedaryl, CF3, halogen; R5, R6, R7 represent C1-alkyl on condition that X9, X10 or X11 in this case respectively equals C; "A" can represent simple bond or bridging ethyne moiety; Y can represent simple bond or is independently selected from methylene or ethylene bridging moieties; moiety Z is independently selected from no-substituted or substituted in nitrogen atom heterocycloalkyl or is non-substituted or substituted cycloalkyl on condition that N (nitrogen) equals C (carbon): , where R9 is selected from CH2OH, CON(R15, R16), where R15, R16 can independently represent H, C1-alkyl, Het represents N, n=1, n1=3; R8 is selected from H, C1-6-alkyl, C1-alkylcarbonyl, derivetives of arylacetic acid of general structure: , where methylheteroaryls of general structure: , where derivatives of alkylsulphonyls of general structure where R14=Alk, with Alk representing C1-alkyl, or to 2-methylamino-1-{3-[6-(6-chloroimidazo[1,2-a]pyridin-3-yl)pyridin-2-ylmethyl]-1-oxa-8-azaspiro]4.5]decan-8-yl}-ethanol dihydrochloride, or to 6-(6- chloroimidazo[1,2-a]pyridin-3-yl)-1',4',5',6'-tetrahydro-2'H-[2,3']bipyridinyl-3'-carboxylic acid dihydrochloride, or to 6-(6- chloroimidazo[1,2-a]pyridin-3-yl)-1',4',5',6'-tetrahydro-2'H-[2,3']bipyridinyl-3'-carboxylic acid dimethylamine dihydrochloride. Invention also relates to pharmaceutical composition based on claimed compound and to method of Haspin kinase inhibition.

EFFECT: obtained are novel compounds, possessing useful biological properties.

5 cl, 7 tbl, 35 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to novel indolopyrrolocarbazole derivatives, which can be used for treating tumours, having the general formula I , where Gly is pentose residues (L-arabinose, D-ribose, D-xylose) and hexose (D-galactose), R is an amino-group, benzamide-group, (pyridin-2-yl) amino-group, acetamide-group or urea-group.

EFFECT: new compounds are proposed, having the pronounced cytotoxic activity.

4 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel crystalline form of N-[-2[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azatidine-sulphonamide, which has an X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1.5418 E and containing, at least, one crystalline peak with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 2 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 3 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1. The said crystalline form can contain additional crystalline peaks with a value 2-theta (in degrees), selected from 12.9 and 18.0, obtained under the said conditions.

EFFECT: crystalline form has the X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1,5418 E, with the crystalline peaks with a value 2-theta (in degrees) 12,9, 13,1, 18,0, 21,0, 22,5, 25,1, 25,3, 28,8, 29,1 and 30,4, and has melting point (beginning) 152,7°C.

6 cl, 3 dwg, 2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, including: i) opening of epoxy cycle of Compound 3 by means of methylamine with obtaining compound 4, ii) separation of Compound 4 by means of chiral acid, selected from L-(-)-malic acid and L-(-)-pyroglutamic acid with obtaining Compound 5A or 5B, or iii protection of secondary amine of Compound 5A or 5B with tert-butoxycarbonyl protective group with obtaining compound 6 iv) methylation of free hydroxyl group of Compound 6 with methylating agent, v) removal of protection from amino groups by means of monohydrate of p-toluenesulphonic acid with obtaining Compound 8 and vi) interaction of Compound 8 with compound 10 with the following obtaining (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.

EFFECT: method improvement.

29 cl, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for the treatment of adenogenous locally advanced cancer of the rectum. For this purpose chemotherapy with 5-fluorouracil, medical therapy, gamma-therapy are realised by a method of dynamic fractioning of a dose. 5-fluorouracil is introduced into the pararectal cellular tissue, adjacent to a tumour, in a volume of 5-15 ml 5-15 min before an irradiation session of before the first three large fractions. As the drug therapy realised is infusion introduction of Mabthera in a dose of 50-70 70 mg/m2 50-60 minutes before radiotherapy on the 1, 7 and 14 days of treatment. From the 1 to 12 days from the treatment beginning radiotherapy is performed on the tumour zone and the zone of regional metastases from 2-4 fields in a mode of dynamic fractioning with SFD=3.6 Gy 3 times and further with SFD=2.2-2.4 Gy 9 times to TFD=32.4-34.8 Gy.

EFFECT: method ensures the reduction of the volume and size of the initial tumour, transfer of non-operable and conditionally operable stages of the disease into the operable state and a possibility of carrying out radical operations with an increase of therapy tolerance as a result of reduction of toxic and cytotoxic effects of the treatment, increase of protective powers of the organism and a possibility of carrying of radiotherapy in the total volume.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to immunology. What is described is an immunoconjugates targeting CD138-expressing cells containing: IgG4 anti-CD138 antibody containing a heavy chain having CDRs from SEQ ID NO: 1 presented in the description and at least 70% identical to SEQ ID NO: 1, and a light chain having CDRs from SEQ ID NO: 2 presented in the description and at least 70% identical to SEQ ID NO: 2; and an effector molecule presenting a tubulin polymerisation inhibitor, and wherein the effector molecule is attached to the above engineered target antibody through a cleaved linker containing a disulphide bond. Besides, disclosed are a pharmaceutical composition and a kit for inhibition, delaying and/or prevention of tumour growth and/or CD138-expressing tumour cell propagation, wherein the composition contains the above immunoconjugate in an effective amount, and one or more pharmaceutically acceptable excipients; the kit comprises pharmaceutical compositions in independent containers, wherein one container comprises an effective amount of the pharmaceutical composition according to the present invention, while the other container contains a second pharmaceutical composition containing an effective amount of a co-drug, preferentially a cytotoxic agent, and one or more pharmaceutically acceptable excipients. There are presented the following methods implying administering the above immunoconjugate: a) a method of treating multiple myeloma in an individual; b) a method for immunoconjugate-mediated drug delivery; c) a method for inhibition, delaying and/or prevention of CD138-expressing tumour cell growth in a cell culture; d) a method for inhibition, delaying and/or prevention of the growth of a tumour containing CD138 tumour cells, and/or propagation of the tumour cells of this tumour in the patient; e) a method for inhibition, delaying and/or prevention of the tumour growth and/or propagation of CD138-expressing tumour cells in the patient; f) a method of treating the individual suffering a condition expected to be improved by suppressing myeloma cell survival; g) a method for inhibition, delaying and/or prevention of the growth of the tumour containing CD138 tumour cells, and/or propagation of the tumour cells in the individual; h) a method for reducing a cell count in a direct or mediated contact to the CD138-expressing tumour cells in the individual; i) a method for reducing a cell count in a direct or mediated contact to the CD138-expressing tumour cells.

EFFECT: invention enables preparing a homogenously targeted agent for treating the CD138-related diseases.

45 cl, 13 dwg, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to immunology. Presented are variants of anti-CD20 modified antibody or its antigen-binding fragment. Each of the variants is characterised by the fact that it contains a variable light and heavy chain domain, and induces a higher apoptosis level as compared to anti-B-Ly1 chimeric antibody. There are presented: a mixture of antibodies, wherein at least 20% of oligosaccharides in Fc domain have a branched chain and are not fucosylated, as well as a pharmaceutical composition for producing a therapeutic agent for a malignant haematological or autoimmune disease by using the antibodies or the mixture of antibodies. Described are: an expression vector, a based host cell, variants of coding polynucleotides, as well as a method for producing the antibody in the cell.

EFFECT: using these inventions provides the new antibodies with the improved therapeutic properties, including with increased binding of Fc receptor, and with the increased effector function that can find application for treating the malignant haematological or autoimmune disease.

32 cl, 3 ex, 9 tbl, 26 dwg

FIELD: medicine.

SUBSTANCE: present invention refers to immunology. Presented is a molecule of bispecific single-chain antibody containing a first binding domain able to bind to epitope of CD3-epsilon-chain of human and Callithrix jacchus (tamarin), Saguinus oedipus (cotton-top tamarin) and Saimiri sciureus (squirrel monkey), and a second binding domain able to bind to an antigen specified in a group consisting of: PSCA, CD19, C-MET, endosialin, EGF-like domain 1 EpCAM coded by exon 2, FAP-alpha or IGF-IR (or IGF-1R) or a human and/or a primate. The epitope CD3e contains an amino acid sequence disclosed in the description. Disclosed are a nucleic acid coding the above molecule of the bispecific single-chain antibody, an expression vector, a host cell and a method for producing the antibody, as well as the antibody produced by the method. Described is a based pharmaceutical composition containing the molecule of the bispecific single-chain antibody and a method for preventing, treating or relieving cancer or an autoimmune antibody. Presented is using the above molecule of the bispecific single-chain antibody for making the pharmaceutical composition for preventing, treating or relieving cancer or the autoimmune disease.

EFFECT: using the invention provides the clinical improvement in relation to T-cell redistribution, reducing it, and the improved safety profile.

23 cl, 74 dwg, 17 tbl, 33 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, more specifically to biospecific antibodies, and can be used in medicine. Constructed is an antibody containing one of the following groups of six hypervariable region (HVR) sequences: (a) HVR-L1 containing the sequence NIAKTISGY; (b) HVR-L2, containing the sequence WGSFLY; (c) HVR-L3 containing the sequence HYSSPP; (d) HVR-H1 containing the sequence NIKDTY; (e) HVR-H2 containing the sequence RIYPTNGYTR; and (f) HVR-H3 containing the sequence WGGDGFYAMD; or (a) HVR-L1 containing the sequence NIAKTISGY; (b) HVR-L2 containing the sequence WGSFLY; (c) HVR-L3 containing the sequence HYSSPP; (d) HVR-H1 containing the sequence NISGTY; (e) HVR-H2 containing the sequence RIYPSEGYTR; and (f) HVR-H3 containing the sequence WVGVGFYAMD. The produced antibody specifically binds human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF) The invention also refers to a recovered Fab fragment of the above antibody, a polynucleotide coding it, to an expression vector, a host cell, a method for producing it, as well as to using it for treating HER2-mediated diseases.

EFFECT: present invention enables producing the bispecific high-affinity antibody able to bind VEGF and HER2 simultaneously.

14 cl, 65 dwg, 16 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, specifically to a fused protein containing a variant of rodostomin, and can be used in medicine. An ανβ3 integrin selective polypeptide consisting of an amino acid sequence SEQ ID NO:1 conjugated on the N terminal by a linker amino acid sequence containing a combination of the amino acids glycine and serine with a variant of a human serum albumin (HSA) with SEQ ID NO:4.

EFFECT: invention enables the higher therapeutic effectiveness in the diseases related to ανβ3 integrin.

12 cl, 14 dwg, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: method involves white rats exposure from the second day of simulated chronic cerebral ischemia. A xiphoid process is covered. The exposure represents electromagnetic waves at the frequency of molecular nitrogen emission and absorption spectrum 150.176-150.664 GHz. The 30-minute exposure has a flow power density of 0.2 mWt/cm2. The exposure is daily, for 6 days.

EFFECT: method provides correcting perfusion and blood flow modulation mechanisms in the cerebral cortex accompanying chronic cerebral ischemia.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in exposing the biologically active points VB 1, TR 23 to THz EHF emission on the frequency of molecular emission and absorption band of atmospheric oxygen of 129.0 GHz. The exposure is generated in the continuous wave mode and covers each point for 5 min each at emission power 100 mcWt. The exposure procedures are daily for 5 days.

EFFECT: higher uncorrected and corrected visual acuity by improving the blood circulation in the central artery of retina, in the lateral short posterior ciliary arteries and ophthalmic arteries.

3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/m3 and exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/m3 and time of exposure of 20 seconds per each 1 cm2 of the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days.

EFFECT: safe and effective conservative treatment of the intestinal fistulas at any phase of the wound process that enables avoiding risks of surgical intervention and general anaesthesia by rapid reduction of skin maceration and perifocal inflammation surrounding the mouth and prevents them, stimulates the growths of granulocyte tissue and epithelisation of the fistuous wound.

FIELD: medicine.

SUBSTANCE: with the underlying conventional drug therapy, the patient is exposed to millimetre-wave electromagnetic emission at the molecular spectrum frequencies of oxygen emission and absorption spectra with the exposure localised within the xiphoid appendix. The exposure time is 3 minutes continuously within one session. The output emissive power is 500 mcW at the power density on the skin surface of 17.4 mcW/cm2. A distance of the exposure point and an object is specified to be equal to 4 cm. The therapeutic course makes 7-10 sessions, one session a day.

EFFECT: higher therapeutic effectiveness in patients with angina or arterial hypertension ensured by the antihypertensive and antianginal effect resulted from the specified mode of the terahertz exposure.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and immunology, and can be used for the assessment of the millimetre-range electromagnetic wave (EHF) effect within a three-component model of cytostatic exposure. That is ensured by a thymus exposure in the group of animals to the millimetre-range electromagnetic wave (EHF) effect at wavelength 5.6 mm for 2 weeks every 1-2 days. A single exposure of the physical factor makes 1-2 minutes for 2 weeks every 1-2 days. That is followed by simulating a surgical intervention by opening and closing a peritoneum. On the seventh postoperative day, the animals are exposed to three-fold fractionated external gamma exposure in a single dose of 2.5 Sv every single day. Thereafter, cyclophosphan is administered intraperitoneally in a dose of 4 mg/100 g of animal's body weight. On the 14th day after the cytostatic is administered, the animals are killed to examine their blood and immune competent organs. That is combined with determining a thymus cellularity (TC) in 106cell./100 mg of its weight, a functional lymphocyte activity in a nitroblue tetrazolium test (NTT) in units, a spleen antibody-forming cell (AFC) count according to N.K.Erne in cells/"чП", apoptosis in an annexin test (AT), %, blood serum circulating immune complex (CIC) in units. That is followed by calculating a physical factor effect index (FI) by formula: FI=AT×NTT×TC×100CIC×AFC. If the FI is less than 48, the presence of the immunomodulatory effect of the EHF-exposure is stated.

EFFECT: method provides the objective assessment of the millimetre-range electromagnetic wave (EHF) effect within the three-component model of the cytostatic exposure.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: impact with a pulsed low-intensity electromagnetic field by means of the INFIT apparatus is performed at the background of standard treatment, an impact duration is 15 minutes; the course of treatment constitutes 10 daily procedures. Additional sessions are carried out daily on the platform coordination, balance, strength (COBS) for 25 minutes; the course of treatment constitutes 10 sessions. The said session is carried out 2 hours after the impact with the pulsed low-intensity electromagnetic field.

EFFECT: method makes it possible to improve the muscular tone, realise correction of present motor skills and form new ones.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to agents for non-invasive microwave energy supply in therapy. A system for microwave energy application to a tissue comprises a signal generator at a frequency within the range of 5 GHz and 6.5 GHz, an irradiator comprising one or more microwave antennas, and a contact area with the tissue with the microwave antenna configured to emit polarised electromagnetic radiation so that an electrical field component of electromagnetic radiation is parallel with the outer layer of skin, a vacuum source coupled with the contact area with the tissue, a cooling source and a controller configured to control the signal generator, vacuum source and cooling source. The system can comprise a fluid chamber arranged between the microwave antenna and the tissue, and a cooling plate between the cooling chamber and the tissue. Also, the system can be presented to generate an energy loss density profile which has a peak energy loss density within a layer of the target tissue. In the microwave energy supply device in the system, a cooling fluid between a cooling element and a microwave energy supply unit has a dielectric constant greater than that of the cooling element. According to the other version, the device comprises a vacuum chamber configured to lift the tissue with the target area, and contacting the tissue with the cooling plate with the cooling plate presented to contact the skin surface above the target area, to cool the skin surface and to separate the skin tissue from the microwave energy supply unit. In a damage formation system, in the first tissue layer, microwave energy from the antenna forms a damage extending within the peak energy loss. According for the other version, a vertical wave structure is generated in the first layer with a distance from a peak constructive interference to the skin surface being more than a distance from the peak constructive interference to an interface of the first and second layers. In a temperature increase system of at least a part of the tissue structure below the interface of a dermal layer and a sub-dermal layer, there is an energy supply unit and a unit for heat removal from the skin surface and at least a part of the upper dermal layer.

EFFECT: using the invention enables to extend the range of aids for microwave therapy.

19 cl, 51 dwg

FIELD: medicine.

SUBSTANCE: method involves a dietary therapy, taking mineral water in an amount of 100-150 ml, 3 times a day and exposure to a physical factor. What is used is the Pevzner's diet No. 5. Karachinskaya chloride-hydrocarbonate sodium gas-free mineral water of total mineralisation up to 3 g/dm3, at a temperature of 38-40°C is taken 30-40 minutes before a meal. The physical factor represents a magnetic laser therapy and an EHF therapy. The contact magnetic laser therapy covers three zones sequentially at a frequency of 5 Hz: an epigastric zone and the right and left upper hypochondria along the midclavicular lines, for 4 minutes for each zone within the course of 10 procedures. The EHF therapy involves combined exposure on two projection zones: in the right hypochondrium and on the sternum generated by a broadband noise emitter at an emission frequency of 40-63 GHz, for 20 minutes, every day within the course of 10 procedures.

EFFECT: method provides more effective rehabilitation treatment following endoscopic cholecystectomy ensured by the early integrated therapeutic exposure.

2 ex, 4 tbl

FIELD: heating.

SUBSTANCE: invention refers to therapeutic systems for releasing energy into the target point. A therapeutic system comprises a therapeutic module for induction heating of the target zone which is made with the possibility of measuring the temperature in the measurement field of the target zone, and a control module for therapeutic module control which is made with the possibility of creating a prior estimate of the induction heating before the energy releases basing on the measured temperature, the successive energy releases are divided by a cooling period. The control module is additionally made with the possibility of prior estimating the cooling period basing on the estimate of the induction heating before the energy releases and with the possibility of adjusting the cooling period basing on the cooling period estimate. Machine readable medium of the system contains a computer programme which is saved on it and, when implemented, order the therapeutic module to perform successive energy releases and includes instructions to create a prior estimate, adjustment of the therapeutic module and creation of prior estimate of the cooling period before the energy releases.

EFFECT: invention allows for improved accuracy of energy releasing into the target zone.

10 cl, 2 dwg

FIELD: heating.

SUBSTANCE: invention refers to therapeutic devices for releasing energy into the target point. A therapeutic system comprises a therapeutic module made with the possibility of successive releases of energy into the target zone, the successive releases are divided by a cooling period, a thermometer module made with the possibility of measuring the maximal temperature in the measurement field placed beyond the focus of the released energy, and a control module made with the possibility of adjusting the cooling period depending on the measured maximal out-of-focus temperature during the period of energy releasing before the cooling period. Machine readable medium of the system contains a computer programme saved on it and including the instructions which, when implemented, order the therapeutic system to perform successive energy releases, measurements of maximal temperature and adjustment of cooling period basing on the measured maximal out-of-focus temperature during the period of energy releasing before the cooling period.

EFFECT: invention allows for improved accuracy of energy releasing into the target zone for more exact setting of the cooling period.

3 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medical equipment. An automated oxygen delivery system comprises an patient's blood flow oxygen measuring sensor comprising a pulse oxymeter; a pneumatic sub-system comprising a gas feed connected to an oxygen inlet, an air inlet and a gas-mixture outlet for mixing oxygen and air to form gas mixture having the oxygen concentration delivered to the patient, and for delivering gas mixture to the patient; and a control sub-system connected to the sensor and the pneumatic sub-system comprising an input. A sensor interface is configured to receive the measurement data and the state information related to the sensor measurement data. The state information involves a perfusion index and a signal quality measure. A pneumatic sub-system interface is used to send commands and to receive the pneumatic sub-system data. A processor is connected to the input, the sensor interface and the pneumatic sub-system interface to control the supplied oxygen concentration on the basis of the required oxygen concentration, the measurement data and the state information. There are disclosed alternative versions of the automated system characterised by state information collecting media.

EFFECT: inventions provide the safe control of the supplied oxygen amount automatically.

27 cl, 5 dwg

Up!